Kaplan-Meier Survival Curves for Gender, Tumor Site, MMR, NLR
and other factors
In this study, 65 patients who received immune checkpoint inhibitors
were included for survival follow-up to determine PFS. The time from the
start of immunotherapy to the occurrence of disease progression or death
due to various causes in these patients was defined as PFS. According to
different factors (including gender, MMR, tumor site, KRAS status, type
of immune checkpoint inhibitor, whether combined with targeted therapy,
whether liver metastatic cancer, whether lymph nodes metastases, and NLR
level), they were divided into different groups, and the Kaplan-Meier
survival curves of each group were plotted separately. The results
showed that in the MMR grouping, there was a statistical difference
between the PFS survival curves of the two, P =0.029, indicating
that patients with dMMR group had a longer PFS and a better patient
prognosis than patients with pMMR group. In addition, in the NLR level
grouping, there was a statistical difference between the PFS survival
curves of the two, P =0.007, indicating that patients in the low
NLR group had longer PFS and better patient prognosis than patients in
the high NLR group. Finally, there was no statistically significant
difference in the PFS survival curves among the groups of gender, tumor
site, KRAS status, type of immune checkpoint inhibitor, whether or not
it was combined with targeted therapy, whether or not it was hepatic
metastatic cancer and whether or not it was lymph nodes metastases,P >0.05, as shown in Figure 1.
Figure 1 Kaplan-Meier Survival Curves for several factors